BeiGene | A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Advanced or Metastatic Solid Tumors

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Advanced or Metastatic Solid Tumors

Beigene Study ID

BGB-B2033-101

ClinicalTrials.gov ID

NCT06427941

Sex: All

Age: 18 Years / N/A

No Study Documents

Locations

Sex: All

Age: 18 Years / N/A

No Study Documents